Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Vetmedica Gmbh

Horst Johann Ahorn

Dieter Blaas

Andreas Zophel

Wolfgang Sommergruber

Timothy Skern

Hans-Dieter Liebig

Birgit Jung

Ingrid Maurer-Fogy

Karl-Heinz Heider

Peter Seither

Hartmut Beug

Renate Konopitzky

Robert E Rhoads

Norbert Kraut

Andreas Weith

Thomas Waerner

Martin Jechlinger

Ido M Tamir

Stefan Gruenert

Elisabeth Ziegler

Regina Kirchweger

Barry J Lamphear

Debra Waters

The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.

Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)

Methods of making and using Picornavirus L proteinase peptides (PLPPs) are provided, including, but not limited to, expression of DNA encoding all or a portion thereof, such as a Picornavirus L proteinase (PLP) and variants thereof, as well as methods for determining active sites and inhibitors of a PLP.

Picornavirus I proteinase and methods of making and using thereof

The invention relates to the expression of mature HRV proteinase 2A, the partial purification thereof and the preparation of substrates having an inhibitory effect.

Expression of mature proteinase 2A, the partial purification thereof and

Growing community of inventors

Weigelsdorf, Austria

Horst Johann Ahorn